Medipost is showing strong performance. This is interpreted as being influenced by the news that PeproMyn Bio, a U.S. immunotherapy development company in which it holds shares, confirmed the disappearance of cancer cells in all three patients during the Phase 1 clinical trial of the ‘BAFFR (Baffal) CAR-T cell therapy’.
As of 10:30 a.m. on the 13th, Medipost is trading at 7,450 KRW, up 4.20% from the previous day.
The day before, PeproMyn Bio held a press conference and announced that in the recent Phase 1 clinical trial of the ‘BAFFR (Baffal) CAR-T cell therapy,’ all three patients’ cancer cells disappeared, confirming its effectiveness. While existing CAR-T therapies target an antigen called CD19, the new therapy is designed to attack an antigen called BAFFR.
The patients participating in the trial suffered from types of blood cancer such as mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma, and had shown no response to existing CAR-T therapies and chemotherapy. However, after administering the BAFFR CAR-T therapy at the lowest dose (50 million cells) for about a year starting in 2022, no cancer was observed in all three patients after 90 days, confirming complete remission. This condition was maintained even after six months.
The research team plans to complete Phase 1 by the end of 2025 and then conduct Phase 2 clinical trials for about two years with 50 to 80 patients. After Phase 2 is completed, they expect to apply for FDA approval and potentially administer the therapy to actual patients as early as 2028.
Meanwhile, Medipost is a company engaged in businesses such as umbilical cord blood storage, health functional food sales, and stem cell therapy development. As of the end of the first half of this year, it holds a 3.41% stake in PeproMyn Bio.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
